This trial is withdrawn!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Chronic Hepatitis C
and you are
between 3 and 17
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

This is a three-part (Part A, Part B, and Part C), open-label, multicenter study of boceprevir in pediatric participants with chronic hepatitis C (CHC) genotype 1 (GT1). In Part A and Part B, efficacy and safety will be evaluated in participants with CHC GT1 who are non-cirrhotic, treatment naïves (Part A) or who are non-cirrhotic, treatment failures to (peg)interferon/ribavirin or who are cirrhotics (whether treatment naïve or treatment failure) (Part B). Part C is long-term follow up and no study treatment will be administered during this period, but participants who do not achieve viral clearance will be allowed to receive other treatments for CHC.

Provided treatments

  • Drug: Boceprevir
  • Drug: Peginterferon alpha-2b
  • Drug: Ribavirin
  • Drug: Boceprevir
  • Drug: Peginterferon alfa-2b
  • Drug: Ribavirin

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01590225. The sponsor of the trial is Merck Sharp & Dohme Corp. and it is looking for 0 volunteers for the current phase.
Official trial title:
A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1